SG11202003864XA - Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression - Google Patents
Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expressionInfo
- Publication number
- SG11202003864XA SG11202003864XA SG11202003864XA SG11202003864XA SG11202003864XA SG 11202003864X A SG11202003864X A SG 11202003864XA SG 11202003864X A SG11202003864X A SG 11202003864XA SG 11202003864X A SG11202003864X A SG 11202003864XA SG 11202003864X A SG11202003864X A SG 11202003864XA
- Authority
- SG
- Singapore
- Prior art keywords
- immortalized
- beta
- car
- eliminate
- genetically modified
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 title 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464457—Telomerase or [telomerase reverse transcriptase [TERT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762598032P | 2017-12-13 | 2017-12-13 | |
PCT/US2018/064971 WO2019118475A1 (en) | 2017-12-13 | 2018-12-11 | Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202003864XA true SG11202003864XA (en) | 2020-07-29 |
Family
ID=66734891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202003864XA SG11202003864XA (en) | 2017-12-13 | 2018-12-11 | Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression |
Country Status (9)
Country | Link |
---|---|
US (2) | US20200332255A1 (he) |
EP (1) | EP3724321A4 (he) |
JP (1) | JP2021506243A (he) |
KR (1) | KR20200088383A (he) |
CN (1) | CN111479917A (he) |
AU (1) | AU2018386010A1 (he) |
CA (1) | CA3082204A1 (he) |
SG (1) | SG11202003864XA (he) |
WO (1) | WO2019118475A1 (he) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
EP3554561B1 (en) | 2016-12-14 | 2023-06-28 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
BR112019012154A2 (pt) | 2016-12-14 | 2019-11-12 | Janssen Biotech Inc | domínios do tipo iii da fibronectina de ligação a cd8a |
EP3554535A4 (en) | 2016-12-14 | 2020-10-21 | Janssen Biotech, Inc. | PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS |
AU2018234810B2 (en) | 2017-03-15 | 2023-05-11 | Pandion Operations, Inc. | Targeted immunotolerance |
SG11201909949XA (en) | 2017-05-24 | 2019-11-28 | Pandion Therapeutics Inc | Targeted immunotolerance |
AU2018304173A1 (en) * | 2017-07-17 | 2020-01-30 | Janssen Biotech, Inc. | Antigen binding regions against fibronectin type III domains and methods of using the same |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
TW202110885A (zh) | 2019-05-20 | 2021-03-16 | 美商潘迪恩治療公司 | 靶向MAdCAM之免疫耐受性 |
PE20220259A1 (es) * | 2019-07-26 | 2022-02-21 | Janssen Biotech Inc | Receptor de antigeno quimerico (car) anti-hk2 |
US11781138B2 (en) | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
EP4045061A4 (en) * | 2019-10-14 | 2024-04-17 | Aro Biotherapeutics Company | FIBRONECTIN TYPE III DOMAINS BINDING TO CD137 |
US20230330239A1 (en) * | 2019-10-14 | 2023-10-19 | Aro Biotherapeutics Company | Epcam binding fibronectin type iii domains |
EP4107187A1 (en) | 2020-02-21 | 2022-12-28 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
US20220332795A1 (en) * | 2021-04-14 | 2022-10-20 | Aro Biotherapeutics Company | Cd71 binding fibronectin type iii domains |
IL311307A (he) * | 2021-09-10 | 2024-05-01 | Kite Pharma Inc | דור אלטנטיבי של תאי t אללוגניים אנושיים |
CN116023496A (zh) * | 2021-10-27 | 2023-04-28 | 深圳市菲鹏生物治疗股份有限公司 | 一种制备通用型car-t细胞的方法及其应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102142385B1 (ko) * | 2011-09-27 | 2020-08-10 | 얀센 바이오테크 인코포레이티드 | 대체 결합 표면을 가진 피브로넥틴 유형 iii 반복체 기반의 단백질 스캐폴드 |
EP4368705A2 (en) * | 2014-03-11 | 2024-05-15 | Cellectis | Method for generating t-cells compatible for allogenic transplantation |
KR102612313B1 (ko) * | 2014-07-21 | 2023-12-12 | 노파르티스 아게 | 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료 |
AU2015339744B2 (en) * | 2014-10-31 | 2021-03-25 | The Trustees Of The University Of Pennsylvania | Altering gene expression in CART cells and uses thereof |
CA2985138A1 (en) * | 2015-05-06 | 2016-11-10 | Janssen Biotech, Inc. | Prostate specific membrane antigen binding fibronectin type iii domains |
AU2016369490C1 (en) * | 2015-12-18 | 2021-12-23 | Sangamo Therapeutics, Inc. | Targeted disruption of the T cell receptor |
BR112018012235A2 (pt) * | 2015-12-18 | 2018-12-04 | Sangamo Therapeutics Inc | rompimento alvejado do receptor de células de mhc |
WO2017112859A1 (en) * | 2015-12-23 | 2017-06-29 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
CN109715199A (zh) * | 2016-09-14 | 2019-05-03 | 詹森生物科技公司 | 包含bcma特异性iii型纤连蛋白结构域的嵌合抗原受体及其用途 |
-
2018
- 2018-12-11 SG SG11202003864XA patent/SG11202003864XA/en unknown
- 2018-12-11 WO PCT/US2018/064971 patent/WO2019118475A1/en unknown
- 2018-12-11 JP JP2020531949A patent/JP2021506243A/ja active Pending
- 2018-12-11 CA CA3082204A patent/CA3082204A1/en active Pending
- 2018-12-11 US US16/770,809 patent/US20200332255A1/en not_active Abandoned
- 2018-12-11 US US16/215,716 patent/US20190175651A1/en not_active Abandoned
- 2018-12-11 CN CN201880080452.1A patent/CN111479917A/zh active Pending
- 2018-12-11 KR KR1020207016631A patent/KR20200088383A/ko active Search and Examination
- 2018-12-11 EP EP18888643.6A patent/EP3724321A4/en active Pending
- 2018-12-11 AU AU2018386010A patent/AU2018386010A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2019118475A1 (en) | 2019-06-20 |
EP3724321A4 (en) | 2021-09-01 |
JP2021506243A (ja) | 2021-02-22 |
CA3082204A1 (en) | 2019-06-20 |
KR20200088383A (ko) | 2020-07-22 |
CN111479917A (zh) | 2020-07-31 |
US20200332255A1 (en) | 2020-10-22 |
US20190175651A1 (en) | 2019-06-13 |
EP3724321A1 (en) | 2020-10-21 |
AU2018386010A1 (en) | 2020-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202003864XA (en) | Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression | |
IL275354A (he) | תרביות משולבות של תאי ואורגנואידי חיסון | |
IL287319A (he) | תאים שעברו שינוי מבחינה גנטית המכילים גן איזור קבוע קולטן אלפא תא t אנושי שעבר שינוי | |
IL259935A (he) | פיצול מכוון של קולטן תא mhc | |
IL267616A (he) | תאים פלוריפוטנטיים מהונדסים מבחינה אימונולגית | |
IL269716A (he) | תאים מופעלי חיסון נוגדן ספציפי | |
IL280718A (he) | מבני תא t ושימושים שלהם | |
IL267543A (he) | תאי nk-92 מאופננים גנטית עם ביטוי מופחת של cd96/tigit | |
SG11201803493UA (en) | Genetically modified cells and uses thereof | |
EP3562492A4 (en) | GENETICALLY MODIFIED NATURAL KILLER CELLS | |
IL250388B (he) | תאי גזע מזנכימליים מותאמים גנטית המבטאים ציטוקין מעורר תגובה חיסונית למשיכת ו/או הפעלת תאים חיסוניים | |
IL248451B (he) | שיטות לבידוד, תרבות והנדסה גנטית של אוכלוסיות תאים אימוניים לטיפול מאמץ | |
IL274025A (he) | קולטן תאי-t חדש | |
IL271412A (he) | תאים סולריים בודדים המחוברים באופן מסיבי | |
LT3307734T (lt) | Branduolinio receptoriaus moduliatoriai (ror), skirti uždegiminių ir autoimuninių ligų gydymui | |
SG11202011392VA (en) | Genetically engineered cell and application thereof | |
SG11202002523YA (en) | Cell compositions comprising antigen-specific t cells for adoptive therapy | |
HK1258886A1 (zh) | T細胞受體及其用途 | |
EP3577234C0 (en) | METHOD FOR SEQUENCING EXPANDED IMMUNE CELL RECEPTORS | |
EP3697895A4 (en) | SYSTEMS AND METHODS FOR PRODUCING GENETICALLY MODIFIED B-CELLS FOR EXPRESSION OF SELECTED ANTIBODIES | |
EP3529267C0 (en) | T CELL RECEPTOR | |
SG11202000811RA (en) | Methods for activating immune cells | |
GB201716746D0 (en) | Deformable support structure | |
IL288922A (he) | חיידקים מהונדסים להפיק תאים ספציפיים לאנטיגן | |
GB201714683D0 (en) | Means and methods to increase plant biomass |